hVIVO plc (ISE: HVO)

Market Cap	246.18M
Revenue (ttm)	67.60M
Net Income (ttm)	18.57M
Shares Out	680.37M
EPS (ttm)	0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Apr 18, 2024

Volume	n/a
Open	n/a
Previous Close	0.322
Day's Range	0.324 - 0.324
52-Week Range	0.170 - 0.360
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, whic...

• Industry: Commercial Physical and Biological Research
• CEO: Yamin Khan
• Employees: 274
• Stock Exchange: Euronext Dublin
• Ticker Symbol: HVO

Financial Performance

Financial numbers in GBP